^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PCDHA1 mutation

    i
    Other names: Protocadherin Alpha 1, Protocadherin Alpha-1, PCDH-Alpha-1, PCDH-ALPHA1, PCDHA1
    Entrez ID:
    56147
    over4years
    Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. (PubMed, Breast Cancer Res Treat)
    Neoadjuvant docetaxel and carboplatin resulted in a pCR of 45.7%. WES and immune profiling differentiated patients with and without pCR.
    Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • RAD51 (RAD51 Homolog A) • IDO1 (Indoleamine 2,3-dioxygenase 1) • COL4A5 (Collagen Type IV Alpha 5 Chain) • CACNA1S (Calcium Voltage-Gated Channel Subunit Alpha1 S) • CFAP58 (Cilia And Flagella Associated Protein 58) • COL22A1 (Collagen Type XXII Alpha 1 Chain) • KPRP (Keratinocyte Proline Rich Protein) • L1CAM (L1 cell adhesion molecule) • PCDHA1 (Protocadherin Alpha 1) • SDK2 (Sidekick Cell Adhesion Molecule 2)
    |
    EGFR mutation • TMB-H • COL4A5 mutation • PCDHA1 mutation • RAD51 mutation
    |
    carboplatin • docetaxel